Patents by Inventor Eduardo Munoz Blanco
Eduardo Munoz Blanco has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230137092Abstract: The present disclosure relates to methods of treating or preventing various diseases or disorders, such as cardiac fibrosis, aortic fibrosis, pulmonary fibrosis, renal fibrosis, dermal fibrosis, and chronic kidney diseases, using cannabidiol derivatives or compositions thereof.Type: ApplicationFiled: February 8, 2021Publication date: May 4, 2023Applicant: EMERALD HEALTH PHARMACEUTICALS INC.Inventors: Alain ROLLAND, Eduardo MUÑOZ-BLANCO, Adela GARCIA-MARTIN, Carmen NAVARRETE
-
Publication number: 20230097024Abstract: It is disclosed a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof: wherein R1 is a linear alkyl group of 3 or 5 carbon atoms, and R2 is: and a pharmaceutical composition comprising the same, for use in the treatment of a disease whose treatment benefits from inhibiting or reducing Notch1 expression levels in cells, and/or benefits from inhibiting or reducing Notch1 levels in cells, and/or benefits from inhibiting or reducing Notch1 signaling dependent proteins levels in cells. As a consequence, present invention also relates to said compound of formula (I), and to the pharmaceutical composition comprising the same, for use in suppressing cancer stem cells, as well as, for use in reducing solid tumor development, metastasis or chemo/radio-resistance, promoted by cancer stem cells.Type: ApplicationFiled: October 24, 2022Publication date: March 30, 2023Inventors: Jon PEÑARANDO SÁEZ, Juan Diego UNCITI BROCETA, Eduardo MUÑOZ BLANCO
-
Patent number: 11583506Abstract: It is disclosed a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof: wherein R1 is a linear alkyl group of 3 or 5 carbon atoms, and R2 is: and a pharmaceutical composition comprising the same, for use in the treatment of a disease whose treatment benefits from inhibiting or reducing Notch1 expression levels in cells, and/or benefits from inhibiting or reducing Notch1 levels in cells, and/or benefits from inhibiting or reducing Notch1 signaling dependent proteins levels in cells. As a consequence, present invention also relates to said compound of formula (I), and to the pharmaceutical composition comprising the same, for use in suppressing cancer stem cells, as well as, for use in reducing solid tumor development, metastasis or chemo/radio-resistance, promoted by cancer stem cells.Type: GrantFiled: October 24, 2022Date of Patent: February 21, 2023Inventors: Jon Peñarando Sáez, Juan Diego Unciti Broceta, Eduardo Muñoz Blanco
-
Publication number: 20220226259Abstract: It is disclosed a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof: wherein R1 is a linear alkyl group of 3 or 5 carbon atoms, and R2 is: and a pharmaceutical composition comprising the same, for use in the treatment of a disease whose treatment benefits from inhibiting or reducing Notch1 expression levels in cells, and/or benefits from inhibiting or reducing Notch1 levels in cells, and/or benefits from inhibiting or reducing Notch1 signaling dependent proteins levels in cells. As a consequence, present invention also relates to said compound of formula (I), and to the pharmaceutical composition comprising the same, for use in suppressing cancer stem cells, as well as, for use in reducing solid tumor development, metastasis or chemo/radio-resistance, promoted by cancer stem cells.Type: ApplicationFiled: April 29, 2020Publication date: July 21, 2022Inventors: Jon PEÑARANDO SÁEZ, Juan Diego UNCITI BROCTETA, Eduardo MUÑOZ BLANCO
-
Publication number: 20220184003Abstract: Compositions, comprising the cannabidiol derivatives of Formula (I) in pharmaceutical formulations displaying increased bioavailability and solubility are described. Cannabidiol derivatives of Formula (I) and compositions comprising the same for use in the treatment of various conditions, and diseases, including diseases associated with demyelination.Type: ApplicationFiled: February 6, 2020Publication date: June 16, 2022Applicant: EMERALD HEALTH PHARMACEUTICALS INCInventors: Alain ROLLAND, Eduardo Munoz BLANCO
-
Publication number: 20220041538Abstract: A compound of formula I or a pharmaceutical salt thereof of formula II, as well as a process to obtain said compound and a process to obtain said salt. Additionally, disclosed is the use of said compound of formula I or said pharmaceutical salt thereof of formula II as a medicament, in particular as a peroxisome proliferator-activated receptor gamma (PPAR?) agonist, for use in the treatment or prevention of a disease responsive to PPAR? agonists. Also disclosed is a pharmaceutical composition comprising said compound or said salt, as well as a method of treating or preventing a disease with said compound of formula I or said salt thereof of formula II, or with a composition comprising said compound or said salt.Type: ApplicationFiled: December 11, 2019Publication date: February 10, 2022Applicant: EMERALD HEALTH PHARMACEUTICALS INCInventors: Eduardo MUÑOZ BLANCO, Giovanni APPENDINO
-
Publication number: 20210317070Abstract: Cannabidiol quinol derivatives of Formula (I) and compositions comprising the same for use in the treatment of conditions that benefit from the inhibition of the HIF prolyl hydroxylases (PHDs) activity are described. Said cannabidiol quinol derivatives of Formula (I), and compositions comprising the same, show thus capacity to inhibit PHD activities and, as a result, stabilize the HIF-1? and HIF-2? levels, activate the HIF pathway in different cell types, induce angiogenesis in human endothelial vascular cell, regulate HIF-dependent gene expression in different cell types and induce collagen contraction. Said cannabidiol quinol derivatives of Formula (I) are useful in the treatment of conditions that benefit from the inhibition of the HIF prolyl hydroxylases (PHDs) activity such as stroke, traumatic injuries anemia, myocardial ischaemia-reperfusion injury, acute lung injury, infectious diseases, diabetic and chronic wounds, organ transplantation, acute kidney injury or arterial diseases.Type: ApplicationFiled: February 16, 2021Publication date: October 14, 2021Inventors: Eduardo MUÑOZ BLANCO, Carmen María NAVARRETE RUEDA, Cristina CRUZ TENO, María Luz BELLIDO CABELLO DE ALBA
-
Patent number: 10919843Abstract: Cannabidiol quinol derivatives of Formula (I) and compositions comprising the same for use in the treatment of conditions that benefit from the inhibition of the HIF prolyl hydroxylases (PHDs) activity are described. Said cannabidiol quinol derivatives of Formula (I), and compositions comprising the same, show thus capacity to inhibit PHD activities and, as a result, stabilize the HIF-1? and HIF-2? levels, activate the HIF pathway in different cell types, induce angiogenesis in human endothelial vascular cell, regulate HIF-dependent gene expression in different cell types and induce collagen contraction. Said cannabidiol quinol derivatives of Formula (I) are useful in the treatment of conditions that benefit from the inhibition of the HIF prolyl hydroxylases (PHDs) activity such as stroke, traumatic injuries anemia, myocardial ischaemia-reperfusion injury, acute lung injury, infectious diseases, diabetic and chronic wounds, organ transplantation, acute kidney injury or arterial diseases.Type: GrantFiled: March 29, 2017Date of Patent: February 16, 2021Assignee: Emerald Health Pharmaceuticals Inc.Inventors: Eduardo Muñoz Blanco, Carmen María Navarrete Rueda, Cristina Cruz Teno, María Luz Bellido Cabello De Alba
-
Patent number: 10766855Abstract: Triterpenoid derivatives and compositions comprising said triterpenoids derivatives of Formula (I) are described, wherein R?—C(O)NHOH. Said triterpenoids and compositions show capacity to bind PHD2, stabilize HIF-1? and HIF-2? proteins, activate the HIF pathway in different cell types, induce angiogenesis in human endothelial vascular cell, show neuroprotective activity in vitro and in vivo, antidiabetic activity and reduce the levels of lipids in vivo, and increase the plasma levels of Erythropoietin in vivo. The triterpenoid derivatives described act also in a selective manner and do not induce Nrf2 activation, NF-?B inhibition, STAT3 inhibition, and TGR5 activation, which are known activities of the natural triterpenoid precursors.Type: GrantFiled: October 3, 2017Date of Patent: September 8, 2020Assignee: VIVACELL BIOTECHNOLOGY ESPAÑA, S.L.Inventors: Eduardo Munoz Blanco, Alberto Minassi, Maria Luz Bellido Cabello De Alba, Giovanni Appendino
-
Publication number: 20200087247Abstract: Cannabidiol quinol derivatives of Formula (I) and compositions comprising the same for use in the treatment of conditions that benefit from the inhibition of the HIF prolyl hydroxylases (PHDs) activity are described. Said cannabidiol quinol derivatives of Formula (I), and compositions comprising the same, show thus capacity to inhibit PHD activities and, as a result, stabilize the HIF-1? and HIF-2? levels, activate the HIF pathway in different cell types, induce angiogenesis in human endothelial vascular cell, regulate HIF-dependent gene expression in different cell types and induce collagen contraction. Said cannabidiol quinol derivatives of Formula (I) are useful in the treatment of conditions that benefit from the inhibition of the HIF prolyl hydroxylases (PHDs) activity such as stroke, traumatic injuries anemia, myocardial ischaemia-reperfusion injury, acute lung injury, infectious diseases, diabetic and chronic wounds, organ transplantation, acute kidney injury or arterial diseases.Type: ApplicationFiled: March 29, 2017Publication date: March 19, 2020Inventors: Eduardo MUÑOZ BLANCO, Carmen María NAVARRETE RUEDA, Cristina CRUZ TENO, María Luz BELLIDO CABELLO DE ALBA
-
Publication number: 20190367447Abstract: Triterpenoid derivatives and compositions comprising said triterpenoids derivatives of Formula (I) are described, wherein R?—C(O)NHOH. Said triterpenoids and compositions show capacity to bind PHD2, stabilize HIF-1? and HIF-2? proteins, activate the HIF pathway in different cell types, induce angiogenesis in human endothelial vascular cell, show neuroprotective activity in vitro and in vivo, antidiabetic activity and reduce the levels of lipids in vivo, and increase the plasma levels of Erythropoietin in vivo. The triterpenoid derivatives described act also in a selective manner and do not induce Nrf2 activation, NF-?B inhibition, STAT3 inhibition, and TGR5 activation, which are known activities of the natural triterpenoid precursors.Type: ApplicationFiled: October 3, 2017Publication date: December 5, 2019Inventors: Eduardo MUNOZ BLANCO, Alberto MINASSI, Maria Luz BELLIDO CABELLO DE ALBA, Giovanni APPENDINO
-
Patent number: 9802880Abstract: The present invention relates to novel cannabigerol quinone derivatives of formula (I) wherein R is the carbon atom of a linear or branched group, represented by: aryl, alkenyl, alkynyl or alcoxycarbonil groups; or wherein R is the nitrogen atom of a linear or branched group, represented by: alkylamino, arylamino, alkenylamino or alkynylamino groups; or, alternatively, R represents a bond between 2 molecules of formula (I) forming a dimer. The invention also relates to the use of any of the compounds of formula (I) as medicaments in therapy, particularly for treating PPARg-related diseases due to their high PPARg agonistic effect lacking electrophilic (Nrf2 activation) and cytotoxic activities. This invention also provides pharmaceutical compositions comprising said compounds and method of treating diseases with said compounds.Type: GrantFiled: February 12, 2015Date of Patent: October 31, 2017Inventors: Giovanni Appendino, María Luz Bellido Cabello De Alba, Eduardo Muñoz Blanco
-
Publication number: 20170247308Abstract: The present invention relates to novel cannabigerol quinone derivatives of formula (I) wherein R is the carbon atom of a linear or branched group, represented by: aryl, alkenyl, alkynyl or alcoxycarbonil groups; or wherein R is the nitrogen atom of a linear or branched group, represented by: alkylamino, arylamino, alkenylamino or alkynylamino groups; or, alternatively, R represents a bond between 2 molecules of formula (I) forming a dimer. The invention also relates to the use of any of the compounds of formula (I) as medicaments in therapy, particularly for treating PPARg-related diseases due to their high PPARg agonistic effect lacking electrophilic (Nrf2 activation) and cytotoxic activities. This invention also provides pharmaceutical compositions comprising said compounds and method of treating diseases with said compounds.Type: ApplicationFiled: February 12, 2015Publication date: August 31, 2017Applicant: VIVACELL BIOTECHNOLOGY ESPAÑA S.L.Inventors: Giovanni APPENDINO, María Luz BELLIDO CABELLO DE ALBA, Eduardo MUÑOZ BLANCO
-
Patent number: 9701618Abstract: The present invention relates to novel cannabidiol quinone derivatives of formula (I) (I) wherein R is the carbon atom of a, linear or branched group, represented by: alkyl, aryl, alkenyl, alkynyl, acyl or alkoxycarbonyl groups; or wherein R is the nitrogen atom of a, linear or branched group represented by: alkylamine, arylamine, alkenylamine or alkynylamine groups. The invention also relates to the use of any of the compounds of formula (I) as medicaments in therapy, particularly for treating diseases and conditions responsive to PPARg modulation due to their high PPARg agonistic effect lacking electrophilic (Nrf2 activation) and cytotoxic activities. This invention also provides pharmaceutical compositions comprising said compounds and method of treating diseases with said compounds.Type: GrantFiled: April 16, 2014Date of Patent: July 11, 2017Inventors: Giovanni Appendino, María Luz Bellido Cabello De Alba, Eduardo Muñoz Blanco
-
Publication number: 20170044092Abstract: The present invention relates to novel cannabidiol quinone derivatives of formula (I) (I) wherein R is the carbon atom of a, linear or branched group, represented by: alkyl, aryl, alkenyl, alkynyl, acyl or alkoxycarbonyl groups; or wherein R is the nitrogen atom of a, linear or branched group represented by: alkylamine, arylamine, alkenylamine or alkynylamine groups. The invention also relates to the use of any of the compounds of formula (I) as medicamentsin therapy, particularly for treating diseases and conditions responsive to PPARg modulation due to their high PPARg agonistic effect lacking electrophilic (Nrf2 activation) and cytotoxic activities. This invention also provides pharmaceutical compositions comprising said compounds and method of treating diseases with said compounds.Type: ApplicationFiled: April 16, 2014Publication date: February 16, 2017Inventors: Giovanni APPENDINO, María Luz BELLIDO CABELLO DE ALBA, Eduardo MUÑOZ BLANCO
-
Patent number: 9416083Abstract: The present invention relates to a new method for isolating ingenol (C20H28O5) from mixtures of diterpenoid esters and ingenol esters in a single step. Ingenol isolated by means of this method can be used as a precursor for the synthesis of biologically active ingenol derivatives, such as ingenol-3-angelate and ingenol-3-tigliate.Type: GrantFiled: October 26, 2015Date of Patent: August 16, 2016Assignee: INDENA S.P.A.Inventors: Maria Luz Bellido Cabello De Alba, Giovanni Appendino, Alberto Pagani, Eduardo Munoz Blanco
-
Publication number: 20160039733Abstract: The present invention relates to a new method for isolating ingenol (C20H28O5) from mixtures of diterpenoid esters and ingenol esters in a single step. Ingenol isolated by means of this method can be used as a precursor for the synthesis of biologically active ingenol derivatives, such as ingenol-3-angelate and ingenol-3-tigliate.Type: ApplicationFiled: October 26, 2015Publication date: February 11, 2016Inventors: Maria Luz Bellido Cabello De Alba, Giovanni Appendino, Alberto Pagani, Eduardo Munoz Blanco
-
Publication number: 20140243551Abstract: The present invention relates to a new method for isolating ingenol (C20H28O5) from mixtures of diterpenoid esters and ingenol esters in a single step. Ingenol isolated by means of this method can be used as a precursor for the synthesis of biologically active ingenol derivatives, such as ingenol-3-angelate and ingenol-3-tigliate.Type: ApplicationFiled: October 2, 2012Publication date: August 28, 2014Inventors: Maria Luz Bellido Cabello De Alba, Giovanni Appendino, Alberto Pagani, Eduardo Munoz Blanco
-
Patent number: 8772349Abstract: Cannabinoid quinone derivatives. The present invention refers to cannabinoid quinone derivatives to be used as medicaments, particularly as PPAR gamma (PPARg) agonists for treating diseases which etiology is based on an impaired PPARg function as transcription factor i.e. PPARg-related diseases.Type: GrantFiled: March 26, 2010Date of Patent: July 8, 2014Assignee: Vivacell Biotechnology Espana, S.L.Inventors: Eduardo Muñoz Blanco, Giovanni Appendino, María Luz Bellido Cabello De Alba
-
Publication number: 20130158126Abstract: Cannabinoid quinone derivatives. The present invention refers to cannabinoid quinone derivatives to be used as medicaments, particularly as PPAR gamma (PPARg) agonists for treating diseases which etiology is based on an impaired PPARg function as transcription factor i.e. PPARg-related diseases.Type: ApplicationFiled: March 26, 2010Publication date: June 20, 2013Applicant: VIVACELL BIOTECHNOLOGY ESPAÑA, S.L.Inventors: Eduardo Muñoz Blanco, Giovanni Appendino, María Luz Bellido Cabello De Alba